香港财政司司长陈茂波：金融、创科、贸易将是香港三个发展引擎 中新社香港12月28日电 香港特区政府财政司司长陈茂波28日发表网志称，2026年是国家"十五五"规划 开局之年，香港将更积极主动对接国家发展战略，金融、创科和贸易将是香港三个重要发展引擎。 针对贸易方面，陈茂波说，面对国际经贸新格局以及产业链和供应链的重塑，香港会继续发挥好"超级 联系人"和"超级增值人"的角色和功能，为"出海"的中国内地企业提供更全面支援。 展望来年，他指出，香港经济可望保持良好势头。市场普遍预期，环球经济即使动力放缓但仍可维持温 和扩张，而内地以至亚洲整体则是主要增长引擎，这些都将继续为香港经济提供重要支撑。此外，市场 预计息率下调，也有利于营商及投资气氛。(完) 来源：中国新闻网 编辑：郭晋嘉 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 近日，香港特区政府财政司司长陈茂波(左一)在添马公园与市民轻松交流。 (香港特区政府财政司 司长网页 ...

以下文章来源于睿兽Pro ，作者Bestla 睿兽Pro . 创业邦旗下横跨一二级市场的科创数据平台。实时投资数据、追踪产业创新。找数据、做分析、链资 源，就上睿兽分析。 全球投融资周报 睿兽分析每周整理当周最值得关注的国内外热门投融资事件，帮助大家及时了解全球市场动向。 一级市场投融资概览 根据睿兽分析监测数据，本周国内一级市场披露的融资事件68个，与上周相比减少13个，其中已披 露融资金额的事件44个，总融资规模为124.69亿元人民币，平均融资金额为2.83亿元人民币。 行业分布 从融资事件数量来看，本周智能制造、人工智能、医疗健康领域融资最活跃。分别为智能制造22 个、人工智能15个、医疗健康10个。 从已披露金额事件的融资规模来看，汽车交通最高，融资总规模约为61.52亿元人民币。其中新能源 汽车研发生产商「长安新能源」完成61.22亿人民币C轮融资。 深蓝汽车科技有限公司，前身为重庆长安新能源汽车科技有限公司，是一家专注于新能源汽车领域的 全产业链企业。公司致力于通过技术创新，打造全场景智慧出行的解决方案，满足用户对高品质、智 能化出行体验的需求。 其次是智能制造行业，已披露融资总额为22.33亿 ...

华福证券指出，结构上创新主线表现突出，CXO和创新药涨幅靠前，而血制品、医药零售、疫苗和IVD 指数跌幅居前。中长期看好三大方向：1）创新药领域，重点关注有商业化能力且管线丰富的BioPharma 和Pharma，以及前沿技术如基因治疗、小核酸等；2）医疗器械方面，医疗设备经过2025年清库存后叠 加新品上市，看好内镜、机器人等板块性机会，同时神经介入、外周介入等创新耗材也是国家重点支持 方向；3）内需消费相关医药公司，受益于中央经济工作会议提出的内需主导政策。此外，随着美联储 降息落地及新版《生物安全法案》通过众议院投票，政策不确定性消除，外需型CXO的海外订单需求 有望持续回暖，板块估值压制或将解除。 疫苗ETF（159643）跟踪的是疫苗生科指数（980015），该指数从市场中选取涉及疫苗研发、生产及销 售等业务的上市公司证券作为指数样本，以反映生物科学特别是疫苗领域相关上市公司证券的整体表 现。该指数聚焦于生物制品、医疗研发等相关领域，具有较高的成长性和创新性特征，适合关注生物医 药行业的投资者配置。 （文章来源：每日经济新闻） ...

本报记者 施 钰 12月1日至3日，由中国侨联、福建省人民政府主办的第三届中国侨智发展大会在福州举行。本届大会 以"侨汇天下才·智创新时代"为主题，吸引来自全球39个国家和地区的上千名专家、学者及海内外专业 机构、社团代表参加。 "福建的人才引进和产业扶持政策非常有吸引力和竞争力。"本届大会，马来亚大学在读博士赵志鑫带着 自己的人机共融式外骨骼机器人项目前来，借大会契机，联系福州相关工业园区、投资方等对接洽 谈，"在接触的过程中，能感受到这里对人才、对科技创新的重视。" 对侨智的支持与吸引，在大会内，更在大会之外。 开展"联侨汇智"海洋经济领域人才交流体验活动，促进国内外海洋经济领域人才合作发展；拓展"侨农 科技之家"服务，签约6项合作项目，促进农业、林业领域海内外人才对接与项目落地……以侨为桥，大 会拓展了海外人才服务站点20个，促成科技合作项目(意向)100余项，达成人才引进意向300余人，推介 高新技术成果450项。 架设"连心桥" 开幕式上，2025年度福州市侨智"揭榜挂帅"专项榜单发布，形成10项技术需求清单。福建医科大学吴孟 超纪念医院成功揭榜福建省星云大数据应用服务有限公司发布的"利用MRI和诊 ...

Group 1 - Seres Group plans to list on the Hong Kong Stock Exchange with a maximum issue price of HKD 131.50 per share, aiming for a total issuance scale of approximately USD 1.7 billion [1] - If priced at HKD 131.50, Seres' market capitalization will reach approximately HKD 215 billion, positioning it alongside other new energy vehicle companies like NIO and Li Auto [1] Group 2 - Huawei's Yu Chengdong has been appointed as the head of the Product Investment Committee while continuing his roles as Executive Director and Chairman of the Terminal BG [2] - Huawei's Pura 80 Ultra and Watch GT 6 Pro have been recognized in Time magazine's list of the best inventions of 2025, highlighting their innovative features [5] Group 3 - "Honor of Kings" has surpassed 139 million daily active users and over 260 million monthly active users globally [3] Group 4 - Following Microsoft's termination of support for Windows 10, the global PC market saw an 8.1% year-on-year growth in Q3, driven by users upgrading to Windows 11 and companies stockpiling to mitigate tariff risks [4] - Lenovo led the market with a 17.4% increase in shipments, while Apple Mac sales grew by 14.9%, making it the second-largest beneficiary [4] Group 5 - NIO announced that its battery swap service has surpassed 90 million swaps, achieving this milestone in just 100 days from the 80 million mark, with an average of over 100,000 swaps per day [7] Group 6 - Two multinational medical giants, AstraZeneca and Medtronic, have announced the establishment of new R&D centers in Beijing, reinforcing China's position as a global hub for medical innovation [8] Group 7 - ByteDance is reportedly developing a new game distribution platform called GameTop, similar to Steam, aimed at providing diverse gaming content and social spaces for overseas users [6]

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) is currently experiencing a decline in stock price, closing at 57.29 yuan with a drop of 3.13%, indicating it is in a state of underperformance since its IPO [1] Group 1: Company Overview - Baicheng Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial issuance of 27.0417 million shares at a price of 79.60 yuan per share [1] - The stock reached a peak price of 120 yuan on its first trading day, marking the highest price since its listing [1] Group 2: Financial Performance - The total funds raised from the initial public offering (IPO) amounted to 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs [1] - The actual net funds raised exceeded the original plan by 1.213 billion yuan, as the company initially aimed to raise 651 million yuan for its headquarters and R&D center project [1] - The total issuance costs for the IPO were 289 million yuan, including underwriting and sponsorship fees of 262 million yuan [1]

Core Viewpoint - The company has completed the acquisition of a property in Irvine, California, for $4.365 million, and established a wholly-owned subsidiary, ETHK BANK, to enhance its operations in the North American market, focusing on stablecoin and intellectual property securitization [1][2]. Group 1: Property Acquisition - The acquired property, located at 9840 Irvine Center Drive, spans approximately 4,960 square feet and includes a two-story office building of about 9,920 square feet, designed for both office and research purposes [2]. - This property will serve as the company's strategic headquarters in the U.S., supporting the development of stablecoin public chain technology and intellectual property securitization, creating a hub for connecting global innovative assets with capital markets [2]. Group 2: ETHK BANK - ETHK BANK will act as the global operational platform for the company's stablecoin and intellectual property securitization business, managing core business directions including stablecoin licensing and compliance framework establishment [3]. - The company is pursuing a federal payment stablecoin issuer license under the U.S. GENIUS Act and plans to apply for a national trust bank license to create a compliant operational system [3]. - The company is developing an innovative stablecoin architecture that supports the generation of stablecoins pegged to the U.S. dollar through real-world asset collateral, aiming to provide a transparent and sustainable digital asset yield solution [3]. Group 3: Key Project Cooperation - The company has signed a strategic cooperation agreement with Transcenta Holding Limited for the tokenization of innovative drug pipeline assets valued at approximately $1.5 billion, with ETHK BANK leading the initiative [5]. - This project focuses on cutting-edge research in cancer treatment, providing a transparent and professional channel for global investors to access medical assets [5]. Group 4: Future Outlook - The acquisition of the U.S. property and the establishment of ETHK BANK signify the company's strategic upgrade towards becoming a global leader in stablecoin and high-tech intellectual property capital operations [6]. - The company aims to integrate on-chain financial infrastructure with the real economy, aligning with global digital economy trends and potentially opening new growth pathways [6]. - The board believes these initiatives reflect the company's core philosophy of transforming knowledge into capital, ensuring long-term stable returns for shareholders through compliant capital operations and innovative practices [6].

Group 1 - Zong Fuli resigned from all positions at Wahaha Group on September 12, 2023, amid negative publicity surrounding the Zong family's reputation and the failed trademark transfer [2] - The resignation is seen as a response to the pressure from the new brand "Wah Xiaozong" and the potential conflict with major shareholders, raising questions about the future of the new brand and its market acceptance [2] - The ability of Hongsheng, the new venture, to innovate and meet consumer trends remains uncertain, especially given Wahaha's strong distribution capabilities [2] Group 2 - Nureat Medical recently completed a D-round financing of approximately 800 million RMB, with participation from several prominent investment firms and funds [5] - The company focuses on the innovation, production, and sales of isotopes and pharmaceuticals, establishing a leading position in the medical isotope and drug development sector [5] Group 3 - Microsoft predicts that data center resource shortages will persist until 2026, affecting Azure cloud service subscriptions in key regions like Northern Virginia and Texas [6] - The ongoing shortage of servers has been a recurring issue for cloud providers, including Microsoft, Amazon, and Google, as they strive to meet customer demand [6] Group 4 - The number of newly opened international air cargo routes in China reached 169 in the first nine months of the year, with significant growth in weekly flights [8] - The routes primarily serve cross-border e-commerce, high-end manufacturing, and other high-value goods, indicating a robust logistics network expansion [8] Group 5 - Multiple cities, including Nanjing, have implemented measures to support the real estate market, particularly for new citizens and young people, in response to market stabilization efforts [9] - The effectiveness of these policy measures remains to be seen, with a focus on stabilizing market expectations [9] Group 6 - Chang'an Automobile announced that its joint venture, Avita Technology, has completed the payment for a 10% stake in Huawei's subsidiary, totaling 11.5 billion RMB [13] - This transaction reflects ongoing strategic partnerships in the automotive and technology sectors [13]

Group 1 - Advances in cutting-edge technologies and therapies are creating unprecedented opportunities for healthy aging [1] - The integration of AI technology in monitoring patient conditions and preventive diagnostics is crucial for managing chronic diseases in the aging population [2] - The development of 3D human-derived neural tissue models for drug research in neurodegenerative diseases shows promise for more effective treatment paradigms [3] Group 2 - Dietary interventions are essential for preventing health issues such as muscle loss, immune decline, and cognitive impairment in the elderly [3] - There is a need for a unified global dietary standard to address the challenges of providing food for approximately 2 billion people amid decreasing agricultural land [4] - Innovative approaches such as plant-based meat, precision fermentation, and cellular engineering are necessary to meet new dietary demands while ensuring biodiversity [4]

Investment Rating - The report assigns a "Buy" rating for the company, marking it as the first recommendation [6][10]. Core Insights - The acquisition of Langyan Life will enhance the company's industrial layout, allowing it to achieve a "CRO + pharmaceutical industry" strategic positioning. Langyan Life specializes in the R&D, production, and sales of high-end chemical drugs and raw materials, which will synergize with the company's R&D services [6]. - The company’s self-developed STC007 injection is entering critical clinical phases, with promising results in its Phase II trials for postoperative pain and chronic kidney disease-related itching. The drug targets peripheral pain relief without central nervous system side effects, indicating a strong market potential [7]. - The company is also advancing in the small nucleic acid drug development sector, with two products in preclinical stages. One product, ABA001, is expected to enter IND status by 2026, indicating a forward-looking approach in drug development [8]. Financial Projections - The company forecasts revenues of 12.59 billion, 14.15 billion, and 16.15 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 2.06, 2.41, and 2.96 yuan. The current stock price corresponds to PE ratios of 32.4, 27.7, and 22.5 for the same years [10][12]. - The projected net profit for 2025 is 231 million yuan, with a growth rate of 30% compared to the previous year. The net profit is expected to continue growing at rates of 16.9% and 22.9% in 2026 and 2027 respectively [12][13].